TNR

Tenascin-R (TNR) is a CNS extracellular matrix glycoprotein required for normal neurodevelopment, as biallelic loss-of-function and missense variants cause a nonprogressive autosomal recessive disorder with spasticity in humans (PMID:32099069) and an analogous exercise-induced paroxysmal dystonia-ataxia syndrome in a canine model carrying a truncating frameshift variant (PMID:37023257). Within perineuronal nets, TNR forms a complex with receptor protein tyrosine phosphatase zeta (RPTPζ) that is anchored to the neuronal surface by the GPI-linked protein contactin-1 (Cntn1), and disrupting Cntn1 binding impairs net structure. TNR also constrains axonal plasticity: it inhibits neurite outgrowth and axonal regeneration after spinal cord injury through a RhoA-dependent mechanism, and antibody antagonism reduces RhoA activation and improves functional recovery (PMID:22902990). TNR is delivered to the matrix through Piccolo-dependent secretion from astrocytes, which supports synaptogenesis and shapes neuronal network activity, and it negatively regulates dopamine receptor D2 (DRD2) expression (PMID:41233622, PMID:41091226).

1. 2012 Medium

   Established that TNR is not merely a structural matrix component but an active inhibitor of axonal regeneration, defining a signaling mechanism through which it limits CNS plasticity.

   Evidence In vitro neurite outgrowth on TN-R substrate with antagonist antibody plus in vivo rat spinal cord hemisection and RhoA activation assay

   PMID:22902990

   Open questions at the time

   • Receptor mediating the RhoA-dependent inhibitory signal not identified
   • Single lab, single injury model
2. 2020 Medium

   Connected TNR loss directly to human disease, establishing that the gene is essential for normal CNS development.

   Evidence Exome sequencing and matchmaking across 13 individuals from 8 families with biallelic variants; clinical phenotyping

   PMID:32099069

   Open questions at the time

   • No functional reconstitution linking specific variants to molecular defect
   • Mechanism connecting perineuronal net loss to spasticity unresolved
3. 2023 Medium

   Demonstrated that TNR loss-of-function causes movement disorders across species, supporting a conserved requirement for TNR in motor circuit function.

   Evidence Whole genome sequencing and genotype-phenotype segregation in 4 affected and 70 unaffected Weimaraner dogs

   PMID:37023257

   Open questions at the time

   • No molecular mechanism study
   • Cellular basis of paroxysmal phenotype unknown
4. 2024 Medium

   Resolved how TNR is physically organized and retained within perineuronal nets, identifying its binding partners and surface anchor.

   Evidence Biochemical fractionation, structural analysis, and cell-surface binding assays with Cntn1 manipulation in a PNN context (preprint)

   Open questions at the time

   • Preprint, single lab
   • Stoichiometry and structural detail of the TNR–RPTPζ–Cntn1 assembly not fully defined
5. 2025 Medium

   Identified the cellular source and secretory route of matrix TNR, linking astrocytic Piccolo-dependent secretion to synaptogenesis and circuit activity.

   Evidence RNA-seq, immunostaining, astrocyte-conditioned media rescue, Pclo gt/gt rat, co-culture synapse density, and electrophysiology (preprint)

   Open questions at the time

   • Preprint, single lab
   • Direct mechanism by which secreted TNR promotes synapse formation not defined
6. 2025 Low

   Extended the disease spectrum to missense variants and proposed a regulatory link between TNR and dopaminergic signaling via DRD2.

   Evidence Exome/Sanger sequencing, Western blot and immunofluorescence, in vitro TNR knockdown with DRD2 readout, BXD systems genetics

   PMID:41091226 PMID:41233622

   Open questions at the time

   • Single molecular readout (DRD2 expression) without mechanistic reconstitution
   • Directness of TNR–DRD2 relationship unestablished
   • Reduced penetrance not mechanistically explained

• The receptor and downstream signaling pathway by which TNR transduces its effects on axon growth, synaptogenesis, and DRD2 regulation remain only partially defined.
• No unified mechanism linking PNN assembly, RhoA-dependent growth inhibition, and dopaminergic regulation
• No structural model of human disease variants